Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sofia Wong"'
Autor:
John Crown, Jonathan W. Goldman, Stephen Chia, Jennifer Marie Suga, Ingrid A. Mayer, Lucía González-Cortijo, Sofia Wong, Cristina Saura, Bruno Perrucci, Alshad S. Lalani, Feng Xu, Andrés Cervantes, Angel Guerrero-Zotano, Valentina Boni, Lisa D. Eli, Komal Jhaveri, Noa Ben-Baruch, François-Clément Bidard, James Waisman, José A. García-Sáenz, Jie Zhang, Barbara Haley, Adam Brufsky, Sherene Loi, Janice Lu, Iben Spanggaard, Mark E. Burkard, Hans Wildiers
Publikováno v:
Cancer Research. 81:PD1-05
Background: HER2 mutations are oncogenic in hormone receptor positive (HR+) metastatic breast cancer (MBC), and may confer resistance to prior endocrine therapy but retain sensitivity to neratinib. Neratinib is an oral, irreversible, pan-HER tyrosine
Autor:
Howard A. Burris III, Susanna Varkey Ulahannan, Eric B. Haura, Sai-Hong Ignatius Ou, Anna Capasso, Pamela N. Munster, Hidenori Kitai, Zhican Wang, Josie Hayes, Lin Tao, Sofia Wong, Yu Chi Yang, Jingjing Jiang, Bojena Bitman, Mallika Singh, W. Clay Gustafson, Neal Rosen, Alison M. Schram
Publikováno v:
Journal of Clinical Oncology. 40:3098-3098
3098 Background: RMC-5552 is a potent bi-steric mTORC1-selective inhibitor that activates the downstream tumor suppressor 4EBP1, thereby inhibiting initiation of protein translation. This novel therapeutic moiety addresses a key limitation of rapalog
Autor:
William G. Wierda, Veerendra Munugalavadla, Renata Walewska, Raquel Izumi, Patricia F. Walker, Alan P Skarbnik, Gillian Corbett, Florence Cymbalista, Yair Herishanu, Wojciech Jurczak, Miklos Egyed, Steven Coutre, Jennifer A. Woyach, John M. Pagel, Manali Kamdar, Ian W. Flinn, Ann Janssens, Laura Fogliatto, George A Follows, Priti Patel, John C. Byrd, Gilles Salles, Min Hui Wang, Sofia Wong, Versha Banerji, Talha Munir, Paolo Ghia, Jeff P. Sharman, Karin Karlsson
Publikováno v:
Lancet
Background: Acalabrutinib is a selective, covalent Bruton tyrosine-kinase inhibitor with activity in chronic lymphocytic leukaemia. We compare the efficacy of acalabrutinib with or without obinutuzumab against chlorambucil with obinutuzumab in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4aef21a30ba224977bc844e26293804
Autor:
Miklos Egyed, Steven Coutre, Laura Fogliatto, Priti Patel, Patricia Walker, Jeff P. Sharman, Raquel Izumi, John M. Pagel, Karin Karlsson, Manali Kamdar, Alan P Skarbnik, Gillian Corbett, George A Follows, Yair Herishanu, Wojciech Jurczak, William G. Wierda, Jennifer A. Woyach, John C. Byrd, Sofia Wong, Veerendra Munugalavadla, Gilles Salles, Min Hui Wang, Talha Munir, Paolo Ghia, Ann Janssens, Versha Banerji, Renata Walewska, Florence Cymbalista
Background: Acalabrutinib is a highly selective, covalent irreversible Bruton tyrosine kinase inhibitor with minimal activity against other kinases. Acalabrutinib has demonstrated durable responses as a single agent or combined with O in treatment-na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e57821e0f24537611656da0e618d163
Autor:
Gary W. Thomas, Nashat Y. Gabrail, Cathy Zhou, George Cole, Alok A. Khorana, Satish Shah, Danelle F. James, Sofia Wong, Ramesh K. Ramanathan
Publikováno v:
Oncology. 96(4)
Objectives: Tissue factor overexpression is associated with tumor progression, venous thromboembolism, and worsened survival in patients with cancer. Tissue factor and activated factor VII (FVIIa) complex may contribute to tumor invasiveness by promo
Autor:
Ashley M. Groves, Balaji Ganeshan, Julien Edeline, Sarah Benafif, Kai-Keen Shiu, Sofia Wong, John Bridgewater, Shih-hsin Chen
Publikováno v:
Cancer Imaging
Aim Following anti-angiogenic treatment, response might be represented by changes in tumour heterogeneity and may not be reflected on traditional size-based criteria. CT texture analysis (CTTA) is one emerging tool to quantify tumour heterogeneity, a